Press Release - NEWS - Zhuhai Beihai Biotech Co., Ltd.

U.S. FDA Formally Accepts Beihai Biotech's New Drug Application for Innovative Oncology Drug BH009 (BEIZRAY™)

2024-01-04
Beihai Biotech Founder Dr. Sun Invited to Keynote 'Wisdom in China' Summit at Renmin University Business School

2023-12-26
Beihai Biotech Successfully Concludes Series C Funding, Expediting BH009 Commercialization and Advancing Clinical Trials for Innovative Drug Candidates

2023-12-19
Beihai Biotech Secures “Drug Manufacturing Certificate”

2023-06-15
Landmark Clinical Research Findings of Beihai Biotech's BH009 Unveiled at ASCO 2023

2023-06-12
贝海生物用于治疗晚期三阴性乳腺癌的创新药物BH009获批开展II期临床试验

2023-04-10
贝海生物BH009新药项目在晚期头颈部鳞癌和卵巢癌患者中的I期临床试验完成首例患者给药

2023-03-09
贝海生物用于治疗非肌层浸润性膀胱癌BH011新药项目II期临床研究完成首例患者给药

2023-03-06

Contact Information

Company address：Blg 2, No. 6366, Zhuhai Ave., Jinwan, Zhuhai, 519090, China
Tel：0756-6349669
Human resources contact：hr@bayhibiotech.com
Business cooperation contact：hjiang@bayhibiotech.com

: Wechat Official Account